Lilly(Eli) & 

$1,129.35
11859
-$3.65-0.32% Monday 20:00

Statistics

Day High
1,137.49
Day Low
1,112.01
52W High
1,182.73
52W Low
623.78
Volume
3,150,305
Avg. Volume
-
Mkt Cap
1.07T
P/E Ratio
40.32
Dividend Yield
0.61%
Dividend
6.92

Upcoming

Dividends

0.61%Dividend Yield
Jun 26
$1.73
Mar 26
$1.73
Dec 25
$1.50
Sep 25
$1.50
Jun 25
$1.50
10Y Growth
12.99%
5Y Growth
15.27%
3Y Growth
15.25%
1Y Growth
15.33%

Earnings

5AugExpected
Q4 2024
Q1 2025
Q2 2025
Q3 2025
Q4 2025
Q1 2026
Next
3.26
5.11
6.96
8.81
Expected EPS
8.810915
Actual EPS
N/A

Financials

31.67%Profit Margin
Profitable
2020
2021
2022
2023
2024
2025
130.36BRevenue
41.28BNet Income

Analyst Ratings

1,252.58Average Price Target
The highest estimate is 1,400.00.
From 12 ratings within the last 6 months. This is not an investment recommendation.
Buy
92%
Hold
0%
Sell
8%

People Also Follow

This list is based on the watchlists of people on Stock Events who follow LLY. It's not an investment recommendation.

Competitors

This list is an analysis based on recent market events. It's not an investment recommendation.

About

Eli Lilly and Company is a prominent global pharmaceutical firm dedicated to the research, development, and commercialization of human medicines across the world. Its therapeutic offerings include a comprehensive suite of diabetes medications. This encompasses various insulin formulations like Basaglar, the Humalog family (e.g., Mix 75/25, U-100, U-200, Mix 50/50), insulin lispro products (including protamine and mix 75/25), and the Humulin line (e.g., 70/30, N, R, U-500). Furthermore, Eli Lilly provides specialized treatments for type 2 diabetes, such as Jardiance, Trajenta, and Trulicity. In oncology, Eli Lilly offers a robust portfolio targeting various cancers. These include Alimta for non-small cell lung cancer (NSCLC) and malignant pleural mesothelioma; Cyramza, indicated for metastatic gastric cancer, gastro-esophageal junction adenocarcinoma, metastatic NSCLC, metastatic colorectal cancer, and hepatocellular carcinoma; Erbitux for colorectal and various head and neck cancers; Retevmo, used in metastatic NSCLC, medullary thyroid, and other thyroid cancers; Tyvyt for relapsed or refractory classic Hodgkin's lymphoma and non-squamous NSCLC; and Verzenio, prescribed for HR+, HER2- metastatic breast cancer, node-positive, and early breast cancer. For autoimmune and inflammatory conditions, the company markets Olumiant for rheumatoid arthritis, and Taltz, which addresses plaque psoriasis, psoriatic arthritis, ankylosing spondylitis, and non-radiographic axial spondyloarthritis. Addressing neurological and pain management needs, Eli Lilly provides Cymbalta for depressive disorder, diabetic peripheral neuropathic pain, generalized anxiety disorder, fibromyalgia, and chronic musculoskeletal pain. Emgality is available for migraine prevention and episodic cluster headaches, while Zyprexa treats schizophrenia, bipolar I disorder, and aids in bipolar maintenance. Other significant products include Bamlanivimab and etesevimab, along with Bebtelovimab, both developed for COVID-19. Cialis is offered for erectile dysfunction and benign prostatic hyperplasia, and Forteo is available for osteoporosis. Eli Lilly actively engages in strategic collaborations with numerous partners, including Incyte Corporation; Boehringer Ingelheim Pharmaceuticals, Inc.; AbCellera Biologics Inc.; Junshi Biosciences; Regor Therapeutics Group; Lycia Therapeutics, Inc.; Kumquat Biosciences Inc.; Entos Pharmaceuticals Inc.; and Foghorn Therapeutics Inc. Established in 1876, Eli Lilly and Company maintains its corporate headquarters in Indianapolis, Indiana.
Show more...
CEO
Mr. David A. Ricks
Employees
47000
Country
United States
ISIN
US5324571083

Listings

0 Comments

Share your thoughts

FAQ

What is Lilly(Eli) & stock price today?
The current price of LLY is $1,129.35 USD — it has decreased by -0.32% in the past 24 hours. Watch Lilly(Eli) & stock price performance more closely on the chart.
What is Lilly(Eli) & stock ticker?
Depending on the exchange, the stock ticker may vary. For instance, on exchange Lilly(Eli) & stocks are traded under the ticker LLY.
Is Lilly(Eli) & stock price growing?
LLY stock has fallen by -1.34% compared to the previous week, the month change is a +12.38% rise, over the last year Lilly(Eli) & has showed a +39.84% increase.
What is Lilly(Eli) & market cap?
Today Lilly(Eli) & has the market capitalization of 1.07T
When is the next Lilly(Eli) & earnings date?
Lilly(Eli) & is going to release the next earnings report on August 05, 2026.
What were Lilly(Eli) & earnings last quarter?
LLY earnings for the last quarter are 8.55 USD per share, whereas the estimation was 6.97 USD resulting in a +22.64% surprise. The estimated earnings for the next quarter are N/A USD per share.
What is Lilly(Eli) & revenue for the last year?
Lilly(Eli) & revenue for the last year amounts to 130.36B USD.
What is Lilly(Eli) & net income for the last year?
LLY net income for the last year is 41.28B USD.
Does Lilly(Eli) & pay dividends?
Yes, LLY dividends are paid quarterly. The last dividend per share was 1.73 USD. As of today, Dividend Yield (FWD)% is 0.61%.
How many employees does Lilly(Eli) & have?
As of June 16, 2026, the company has 47,000 employees.
In which sector is Lilly(Eli) & located?
Lilly(Eli) & operates in the Health & Wellness sector.
When did Lilly(Eli) & complete a stock split?
Lilly(Eli) & has not had any recent stock splits.
Where is Lilly(Eli) & headquartered?
Lilly(Eli) & is headquartered in Indianapolis, United States.